Articles tagged with Breast Cancer
Researchers found correlations between MRI measures and histopathological markers of breast cancer, suggesting the potential for MRI in predicting disease prognosis and guiding targeted therapies. The study's findings could lead to improved understanding of breast cancer biology and more accurate treatment planning.
Women with BRCA1 or BRCA2 mutations are at high risk for developing contralateral breast cancer, and certain subgroups are more susceptible based on age and first tumor status. The study found that carriers have a 17.9% 10-year risk, while non-carriers have a 6.0% risk.
A phase II multi-institutional study of women at increased risk for breast cancer evaluated the safety and efficacy of exemestane over two years, showing steady decreases in 'good' cholesterol levels. While this effect may prove significant for women at high risk for heart disease, its clinical significance remains unknown.
Whole-genome sequencing reveals activation of targets for new treatment strategies, including MEK/AKT inhibitors for metastatic triple negative breast cancers. The study's results indicate potential for improved treatment options for nearly 20% of breast cancers that do not respond to targeted therapies.
A study by Mayo Clinic researchers found that obese patients with HER2-positive breast cancer had poorer outcomes, larger tumors, and were more likely to have lymph node involvement compared to normal-weight patients. The study's lead author notes that excess body weight may affect treatment outcome for this subtype of breast cancer.
Research found obesity associated with shorter time to recurrence and disease-free survival in early-stage breast cancer. However, treatment with endocrine therapy showed a protective effect against obesity-related poor outcomes.
Researchers found that a combination of anti-estrogen drugs anastrozole and fulvestrant can lengthen the lives of post-menopausal women with hormone receptor-positive metastatic breast cancer. The therapy also showed promise in patients who had not previously received tamoxifen therapy.
A new study by researchers from the University of Pennsylvania School of Medicine found that contralateral prophylactic mastectomy (CPM) provides only a modest increase in life expectancy among women with unilateral breast cancer. The surgery may actually reduce quality-adjusted life expectancy for patients without hereditary factors.
A German study found no improvement in disease-free survival among breast cancer patients treated with dose-dense chemotherapy and oral ibandronate. The results contradict previous studies, which showed benefits in postmenopausal patients receiving zoledronic acid or endocrine treatment.
Researchers found that adding pertuzumab to trastuzumab and docetaxel chemotherapy extended progression-free survival by 6.1 months, with a 38% reduction in risk for progression. The three-drug combination was also remarkably safe and well-tolerated.
Researchers found a median progression-free interval of 7.4 months for patients treated with exemestane and everolimus, compared to 3.2 months for those receiving placebo. Clinical benefit rates were also higher in the combined treatment group, with 50.5% experiencing complete response or stable disease.
The addition of zoledronic acid to adjuvant endocrine therapy increased bone mineral density and reduced disease recurrence among postmenopausal women with early hormone receptor-positive breast cancer. Immediate zoledronic acid use also improved survival outcomes, particularly in women who were truly menopausal at diagnosis.
Breast cancer mortality is higher in Hispanic women compared to non-Hispanic white women, with a 20% increased risk of death. The ethnic disparity may be attributed to tumor phenotypes less responsive to chemotherapy, which affects long-term survival rates.
A recent study found that clodronate had a low incidence of adverse events and toxicity among patients with breast cancer. The treatment modestly reduced the incidence of distant metastases in postmenopausal women, with a relative reduction of 9% compared to placebo.
Researchers confirm zoledronic acid's continued effectiveness in reducing breast cancer recurrences and improving survivorship rates among premenopausal women with estrogen receptor-positive breast cancer. The study found a 28% reduced risk for recurrence and a 36% reduction in mortality risk, with no toxic side effects.
The addition of bevacizumab to trastuzumab and docetaxel improved progression-free survival in patients with HER2-positive, locally recurrent/metastatic breast cancer. Median progression-free survival increased by 2.8-2.9 months with bevacizumab.
Researchers found that combining everolimus and exemestane significantly improved progression-free survival by 4.2 months, with a clinical benefit rate of 50.5% in the combination arm. The study suggests a new approach for treating hormone-resistant breast cancer, which may change treatment practices.
A new study found that taking two breast cancer medications together, anastrozole and fulvestrant, significantly extended the lives of women with metastatic breast cancer. Women who received the combination treatment lived over six months longer than those who took the drugs in sequence.
A new triple drug combination has been shown to increase tumour eradication in HER2-positive breast cancer by more than half, with 46% of patients achieving a pathological complete response. The treatment was well-tolerated and did not significantly increase side effects or cardiac risk compared to standard therapy.
Researchers at Tel Aviv University have developed a radioactive wire that destroys tumors from the inside out, creating an immunity against cancer return. This innovative method, called DARTTM, has shown promising results in pre-clinical trials and is now being commercialized for clinical trials.
A retrospective study found that women treated with accelerated partial breast irradiation therapy have a two-fold increased risk for subsequent mastectomy, most likely due to tumor recurrence or local complications. APBI brachytherapy was also associated with higher incidence of acute and late toxicities compared to traditional whole ...
A significant number of women with breast cancer are not receiving guideline-recommended adjuvant treatment. The research found that socioeconomic factors such as poverty, insurance status, and education level significantly contribute to this disparity. Women from high-poverty areas were less likely to receive guideline therapy, highli...
Researchers developed a multigene test to identify high-risk patients with ductal carcinoma in situ (DCIS) and differentiate between lower-risk and more aggressive forms. The DCIS Score algorithm predicts individual risk for recurrence, allowing physicians to provide tailored treatment programs.
A study found significant gene expression patterns among tumor samples that correlated with distant metastatic disease development. These patterns may help personalize treatment and predict which patients are likely to recur early or late.
Research found that diabetes increases breast cancer risk by 37% in women diagnosed within four years of cancer development. Obesity after age 60 also significantly increases the risk, with a 55% increase in breast cancer cases compared to the general population. High and low blood lipids were also associated with different risks.
A research team discovered distinct gene patterns associated with early and late breast cancer recurrences, which could help predict patient outcomes and guide personalized therapy. The findings may enable oncologists to delay or prevent recurrences and reduce excessive treatment for patients who will not recur.
Women treated with brachytherapy experienced a twofold increased risk for losing their breasts compared to those treated with whole-breast irradiation. Brachytherapy also led to nearly a twofold higher risk of postoperative infections and complications, as well as radiation-related side effects.
Researchers found that dopamine injections improved blood flow to tumors, doubling the concentration of an anticancer drug and increasing its effectiveness. Dopamine also normalized the structure of abnormal tumor blood vessels, a condition typically associated with reduced chemotherapy and radiation therapy effectiveness.
Researchers will collect cancer incidence data from 13 Appalachian states to identify differences in relative survival and avoidable death between sub-regions and non-Appalachian areas. The findings will inform the development of effective evidence-based cancer control interventions for the region.
A meta-analysis of 123 randomised trials involving 100,000 women with breast cancer shows that modern chemotherapy regimens reduce breast cancer mortality by around one-third compared to no chemotherapy. The findings suggest that standard 1980s chemotherapy regimens could produce a reduction of almost a quarter in breast cancer mortality.
University of Missouri researchers say exercise is beneficial for breast cancer survivors and patients with lymphedema, outweighing risks. Patients at risk can exercise without increasing the risk of developing lymphedema, according to a new literature review.
The study reveals co-activating events in the MAPK and PI3K/AKT pathways, leading to targeted treatments with significant patient benefits. Physicians steered patients into tailored treatment plans based on sequencing data, resulting in improved outcomes.
Researchers have developed a new tumor-targeting compound called PU-H71 that can reveal the complete set of aberrant signaling pathways driving cancers in individual patients. This breakthrough method uses the compound to identify abnormal proteins bound to heat shock protein 90, which are crucial for cancer cell growth and survival.
Researchers at Thomas Jefferson University identified breast cancer cell mitochondria as a key target for therapy, showing that off-patent generic drug Metformin can prevent tumor growth and chemotherapy resistance. The study's findings suggest that targeting mitochondrial metabolism could be exploited in personalized cancer medicine.
A new study published at the Radiological Society of North America meeting found that women between 40-49 years old without a family history of breast cancer are equally likely to develop invasive breast cancer as those with a family history. Annual screening mammography is recommended for this age group.
A new study published in Cancer Discovery reveals that the 14-3-3σ gene plays a critical role in halting breast cancer initiation and progression. The research suggests that this gene is likely a major player in other types of cancer as well.
A new study shows that comparing a new biopsy of recurrent breast cancer with the original biopsy can dictate a change in treatment. The results suggest that patients may benefit from asking their physician if a second biopsy is needed to confirm their treatment therapy.
Experts from NYU Langone's Department of Radiology will present on various topics, including genitourinary evaluations and breast MRI outcomes. The department is a leader in advanced diagnostic imaging with over 100 board-certified radiologists.
Research found a significant link between women with lobular breast cancer and fathers with prostate cancer, with the risk of lobular cancer almost doubling when considering family history. The connection was independent of hormone receptor status.
A new study by Michigan State University researchers found that metformin prevents tumors from growing in human cultures, providing biological evidence for its potential to reduce the risk of diabetes-associated cancers. The research suggests that metformin may be used as a preventive drug for individuals with Type-2 diabetes.
Researchers at Moffitt Cancer Center found that men are less willing to be screened for cancer despite having higher mortality rates. The study suggests that better health and cancer screening promotion among men can improve existing practices.
The new guidelines recommend no routine mammography screening for women aged 40-49, and extend the screening interval to every 2-3 years for women aged 50-74. The task force also advises against routine clinical breast exams and breast self-exams in asymptomatic women.
Researchers at the University of Michigan Comprehensive Cancer Center discovered two cancer-spurring gene rearrangements that may trigger 5 to 7 percent of all breast cancers. These rearrangements, seen in the MAST kinase and Notch family genes, can give scientists targets for potential therapies.
A recent study found that women taking combination estrogen and progestin menopausal hormone therapy are at a greater risk of developing breast cancer if they experience new onset breast tenderness. In contrast, women on estrogen alone without breast tenderness did not have an increased risk of breast cancer.
Research reveals PBX1's role in breast cancer progression by modulating chromatin compaction and promoting ERα recruitment. The discovery holds promise for developing prognostic markers and therapeutic strategies to prevent breast cancer progression.
Despite widespread adoption, MRI's limited evidence supports its benefit only for high-risk women and no significant impact on treatment outcomes. MRI's increased sensitivity in detecting cancer has yet to translate into better patient selection or reduced surgical procedures.
Despite advancements in genetic profiling, breast cancer treatment remains non-personalized due to limited robust prognostic and predictive factors. Standard gene expression profiling has shown limitations in predicting chemotherapy benefit and prognosis for certain disease subsets.
A study published in Annals of Oncology found that nearly half of male breast cancer patients on tamoxifen experience significant side effects, including weight gain and sexual dysfunction. The research highlights the need for better understanding and awareness of treatment risks and benefits.
A large study found that 53% of male breast cancer patients experience tamoxifen-related side effects, leading to early discontinuation. The study suggests that these patients may be at increased risk of cancer recurrence.
Researchers identified a key interaction between BRCA1 and RHAMM proteins regulating epithelial cell polarity, found altered in some breast cancer patients. The discovery provides new insights into the molecular mechanisms driving breast cancer development.
A new study found a significant association between adolescent alcohol consumption and increased risk of benign breast disease among girls with a family history of breast cancer. Consuming more alcohol was linked to a higher risk, particularly in those with rapid height growth spurts.
A new study from Washington University School of Medicine finds that adolescent girls with a family history of breast disease have a higher risk of developing benign breast disease as young women, and this risk rises with increasing alcohol consumption. The researchers suggest limiting alcohol intake to lower risk or avoid increasing it.
A study published in Archives of Neurology found that breast cancer survivors who received chemotherapy demonstrated reduced activation in key brain areas and poorer executive function. The researchers also discovered that negative effects of chemotherapy may be exacerbated by factors such as age and educational level.
Researchers at George Mason University have identified a key driver in inflammatory breast cancer, allowing for the development of new treatments. The study found that nearly all samples had high activation of the protein anaplastic lymphoma kinase (ALK), paving the way for targeted therapy.
Researchers identified ALK amplification in up to 86% of inflammatory breast cancer patients, a potentially targeted therapy approach. Inhibiting ALK with a small-molecule inhibitor resulted in tumor cell death, paving the way for clinical trials.
UCSF researchers have discovered the molecular basis for tamoxifen resistance and found a potential way to defeat it. They showed that cells can develop resistance through epigenetic modification, specifically by elevating expression of the 'survival' gene AKT.
A combination of REGN910 and aflibercept has been shown to inhibit tumor growth more effectively than single-agent therapies, with significant improvements in antitumor effects observed in animal models. The treatment also induced increased tumor hypoxia, leading to rapid cell death and dramatic regression in colorectal tumors.
Researchers found that introducing a novel histone deacetylase inhibitor can reverse tumor's survival strategy and stop resistance, leading to higher cell death rates. This approach may prevent hormone therapy resistance in patients with estrogen receptor-positive breast cancer.
Researchers at McGill University Health Centre have identified parathyroid hormone-related protein (PTHrP) as a key player in breast cancer progression and metastasis. The study found that blocking PTHrP production can reduce tumor growth by 80-90% and prevent its spread to other organs.
A Stanford team developed a machine-learning-based method called Computational Pathologist (C-Path) to analyze breast cancer microscopic images, outperforming human evaluations. The model assesses 6,642 cellular factors and identifies structural features that matter in predicting patient survival.